Test availability at launch can be underestimated, under-budgeted and under-resourced: an example using real-time, real world analysis of PD-L1

Diaceutics gave a presentation at TriCON 2017 discussing how biomarkers and diagnostics are still falling short at launch, even though the industry is no longer in its infancy. Here, Jordan Clark, Managing Director, reports on how we can track the real-time, real-world development of PD-L1 in NSCLC and highlights the differences in the test’s availability, budgeting and resourcing.
Existing Users Log In